Saturday 17 October 2026
Export APUS’s income statement to Excel — free account
Apimeds Pharmaceuticals US, Inc.
APUS Healthcare Drug Manufacturers Specialty & Generic
In the quarter to June 2026, EPS fell 352.7%, free cash flow fell 67.9% and total debt rose 2,468.3%, each against the same quarter a year earlier.
4.04
0.35
−7.97%
Follow APUS
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+7 more TTM periods Free account |
(125.91%) | (7.90%) | (65.22%) | (100.13%) | |
| (106.66%) | (7.31%) | (57.48%) | (84.20%) | ||
ROIC |
(274.01%) | (5.00%) | (11.96%) | (15.96%) | |
Return on Tangible Assets |
(64.23%) | (180.27%) | 2,956.78% | 562.41% | |
Free Cash Flow per Share |
(4.17) | (8.25) | (7.12) | (7.78) | |
Free Cash Flow |
(5.24) | (8.98) | (11.04) | (13.33) | |
Capital Expenditures |
(0.04) | (0.06) | (0.07) | (0.05) | |
| Other line items | |||||
Cash ROIC |
(34.62%) | (5.22%) | (7.62%) | (10.78%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
— | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
— | — | 0.00% | 0.00% | |
Interest Coverage |
(49.73) | (42.09) | (21.49) | (6.35) | |
Operating CF/Net income |
1.01 | 1.49 | 0.27 | 0.23 | |
Depreciation/Fixed assets |
0.05 | 0.11 | 0.45 | 0.88 | |
Capex/Depreciation |
(21.12) | (10.05) | (2.60) | (1.16) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(4.14) | (8.20) | (7.07) | (7.75) | |
Capex per Share |
(0.03) | (0.05) | (0.04) | (0.03) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates